Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Hayward, CA-based company was founded in 2015 and booked $1 million in sales for the 12 months ended December 31, 2017. It plans to list on the NYSE under the symbol RCUS. Citi, Goldman Sachs and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
